Literature DB >> 17986543

Setting up a continuous ambulatory peritoneal dialysis training program.

Irene L L Kong1, Irene L P Yip, Grace W S Mok, Soso Y M Chan, Candic M K Tang, Sharon W Y Wong, Rebecca B T Tsui, Wai-kay Tsang, Samuel K S Fung, Hilda W H Chan, Matthew K L Tong.   

Abstract

Continuous ambulatory peritoneal dialysis (CAPD) training programs have become fundamental patient education programs in renal centers providing peritoneal dialysis (PD) services. Several key topics must be addressed in setting up a CAPD training program: Health care and organizational issues, Multidisciplinary team approach, Evidence-based practice, Pre-training patient assessment, Patient training Program evaluation. The PD nurses should identify key learning objectives for patient training. The essential elements of CAPD training are the training content and schedule, training assessment, and teaching methods. Program set-up also includes establishing a back-up system and follow-up protocols, which are essential for continuity of care in renal patients. Outcomes such as rates of peritonitis and exitsite infection, unplanned readmission, and patient satisfaction are all important indicators when the results of CAPD training programs are reviewed. The development and successful implementation of a cost-effective CAPD training program has a significant impact on patient outcomes in the renal specialty.

Entities:  

Mesh:

Year:  2003        PMID: 17986543

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  2 in total

1.  Advanced nursing experience is beneficial for lowering the peritonitis rate in patients on peritoneal dialysis.

Authors:  Zhikai Yang; Rong Xu; Min Zhuo; Jie Dong
Journal:  Perit Dial Int       Date:  2011-06-30       Impact factor: 1.756

Review 2.  Review of predialysis education programs: a need for standardization.

Authors:  Judith Van den Bosch; D Simone Warren; Peter A Rutherford
Journal:  Patient Prefer Adherence       Date:  2015-09-09       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.